Maria Jové

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz et al. · Science Translational Medicine · 2020 · 80 citations

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo et al. · Journal of Clinical Oncology · 2018 · 68 citations

Surgical Oncology, Medicine, High Response Rate +12

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2021 · 67 citations

Tumor Biology, Molecular Pharmacology, Dose Finding Study +14

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · Journal of Clinical Oncology · 2019 · 61 citations

Surgical Oncology, Conventional Chemotherapy, Phase Ii +14

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Laura Mezquita, Maria Jové, Ernest Nadal et al. · Journal of Thoracic Oncology · 2020 · 54 citations

Li-fraumeni Syndrome, High Prevalence, Pathology +2